Biogen (BIIB) Stock Forecast & Price Target

$140.64 +3.56 (+2.60%)

Closing price 02/21/2025 04:00 PM Eastern

Extended Trading

$140.62 -0.02 (-0.02%)

As of 02/21/2025 07:52 PM Eastern

Biogen - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 30 Analyst Ratings

Sell
0

Hold
17

Buy
13

Based on 30 Wall Street analysts who have issued ratings for Biogen in the last 12 months, the stock has a consensus rating of "Hold." Out of the 30 analysts, 17 have given a hold rating, and 13 have given a buy rating for BIIB.

Consensus Price Target

$213.33
51.69% Upside

According to the 30 analysts' twelve-month price targets for Biogen, the average price target is $213.33. The highest price target for BIIB is $342.00, while the lowest price target for BIIB is $135.00. The average price target represents a forecasted upside of 51.69% from the current price of $140.64.

Get the Latest News and Ratings for BIIB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Biogen and its competitors.

BIIB Analyst Ratings Over Time

Type	Current Forecast 2/24/24 to 2/23/25	1 Month Ago 1/25/24 to 1/24/25	3 Months Ago 11/26/23 to 11/25/24	1 Year Ago 2/24/23 to 2/24/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	12 Buy rating(s)	15 Buy rating(s)	19 Buy rating(s)
Hold	17 Hold rating(s)	16 Hold rating(s)	13 Hold rating(s)	8 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$213.33	$230.00	$257.20	$305.68
Forecasted Upside	51.69% Upside	57.32% Upside	62.06% Upside	36.88% Upside
Consensus Rating	Hold	Hold	Moderate Buy	Moderate Buy

BIIB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BIIB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biogen Stock vs. The Competition

Type	Biogen	Medical Companies	S&P 500
Consensus Rating Score	2.43	2.82	2.53
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	51.69% Upside	29,257.97% Upside	14.34% Upside
News Sentiment Rating	Positive News See Recent BIIB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/18/2025	Piper Sandler 2 of 5 stars	Christopher Raymond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$138.00 ➝ $135.00	-2.59%
2/13/2025	Scotiabank 5 of 5 stars	George Farmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sector Outperform ➝ Sector Outperform	$244.00 ➝ $224.00	+61.69%
2/13/2025	BMO Capital Markets 4 of 5 stars	E. Seigerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Perform ➝ Market Perform	$156.00 ➝ $139.00	+1.30%
2/13/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$281.00 ➝ $245.00	+78.99%
2/13/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$192.00 ➝ $157.00	+14.70%
2/13/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Meacham Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$160.00 ➝ $145.00	+6.96%
2/13/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$231.00 ➝ $225.00	+65.98%
2/13/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$165.00 ➝ $140.00	+4.40%
2/13/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Srikripa Devarakonda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$220.00 ➝ $210.00	+57.39%
2/13/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Fein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$300.00 ➝ $241.00	+80.62%
Get the Latest News and Ratings for BIIB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.
2/13/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Fadia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
2/13/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Sumant Kulkarni Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$298.00 ➝ $265.00	+98.61%
2/11/2025	Bank Of America (Bofa) Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$178.00 ➝ $163.00	+16.94%
2/11/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Gal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$160.00	+12.25%
1/13/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
12/16/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$175.00	+16.64%
12/10/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral	$178.00	+13.77%
12/9/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$250.00 ➝ $180.00	+14.08%
11/21/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$251.00 ➝ $207.00	+32.69%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
11/15/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$294.00 ➝ $300.00	+81.94%
11/4/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$220.00 ➝ $210.00	+22.40%
10/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$190.00 ➝ $180.00	+2.18%
10/31/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$270.00 ➝ $255.00	+44.75%
10/31/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$300.00 ➝ $275.00	+56.24%
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/3/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Verma Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$234.00 ➝ $202.00	+9.42%
9/23/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$210.00 ➝ $205.00	+4.17%
9/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$292.00 ➝ $292.00	+46.34%
5/3/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$339.00 ➝ $342.00	+57.23%
1/7/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Shrader Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
8/8/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$282.00 ➝ $275.00	+1.39%
5/11/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$320.00 ➝ $350.00	+11.73%
5/1/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$270.00 ➝ $350.00	+15.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:41 AM ET.

Should I Buy Biogen Stock? BIIB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, February 16, 2025. Please send any questions or comments about these Biogen pros and cons to contact@marketbeat.com.

Biogen
Bull Case

Here are some ways that investors could benefit from investing in Biogen Inc.:

Biogen Inc. reported a strong quarterly earnings per share (EPS) of $3.44, exceeding analysts' expectations, which indicates robust financial performance and potential for future growth.
The company has a market capitalization of $20.01 billion, suggesting it is a well-established player in the biotechnology sector, which can provide stability for investors.
With a price-to-earnings (P/E) ratio of 12.41, Biogen Inc. appears to be undervalued compared to the industry average, potentially offering a good entry point for investors.
The stock is currently trading at approximately $146.90, which is significantly above its 52-week low of $128.51, indicating a positive trend in stock performance.
Institutional investors hold 87.93% of Biogen Inc.'s stock, reflecting strong confidence from large financial entities in the company's future prospects.

Biogen
Bear Case

Investors should be bearish about investing in Biogen Inc. for these reasons:

The company has a beta of -0.08, indicating that its stock price is less volatile than the market, which may limit potential high returns for aggressive investors.
Biogen Inc. has a debt-to-equity ratio of 0.28, which, while relatively low, suggests that the company is not leveraging debt to fuel growth, potentially missing out on expansion opportunities.
The price-to-earnings-growth (PEG) ratio of 1.65 indicates that the stock may be overvalued relative to its expected earnings growth, which could deter value-focused investors.
Recent trading volume of 1,690,446 shares is above the average of 1,234,164, which could indicate increased selling pressure or volatility in the stock.
Despite a solid net margin of 16.81%, the competitive landscape in biotechnology means that Biogen Inc. faces ongoing challenges from other firms, which could impact future profitability.

BIIB Forecast - Frequently Asked Questions

: According to the research reports of 30 Wall Street equities research analysts, the average twelve-month stock price forecast for Biogen is $213.33, with a high forecast of $342.00 and a low forecast of $135.00.
: 30 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 17 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BIIB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIIB, but not buy additional shares or sell existing shares.
: According to analysts, Biogen's stock has a predicted upside of 51.69% based on their 12-month stock forecasts.
: Over the previous 90 days, Biogen's stock had 4 downgrades by analysts.
: Biogen has been rated by research analysts at Bank Of America (Bofa), Bank of America, BMO Capital Markets, Canaccord Genuity Group, Citigroup, HC Wainwright, Jefferies Financial Group, Morgan Stanley, Needham & Company LLC, Piper Sandler, Royal Bank of Canada, Sanford C. Bernstein, Scotiabank, Stifel Nicolaus, The Goldman Sachs Group, Truist Financial, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like Biogen less than other "medical" companies. The consensus rating for Biogen is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BIIB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:BIIB) was last updated on 2/23/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biogen (BIIB) Stock Forecast & Price Target